1024953-89-6

Upstream product

• 1024954-75-3 ethyl 4-[(2,4-difluorophenyl)amino]-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxylate 
• 1024955-77-8 4-(2-ethoxy-4-nitrophenyl)pyridine 
• 1692-15-5 4-pyridylboronic acid 
• 1024955-27-8 ethyl 4-chloro-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxylate 
• 1025216-24-3 C₁₄H₂₂N₂O 
• 1024955-56-3 4-(2-ethoxy-4-nitrophenyl)-1-methylpyridinium iodide 
• 423165-33-7 1-bromo-2-ethoxy 4-nitrobenzene 

Relevant academic research and scientific papers

Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507

The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the huma